Sigrid Therapeutics Raises SEK 45M in Funding

The new capital supports US growth for Glucose Stabiliser and development of additional SiPore applications.

Round size
SEK 45M
Stage
Undisclosed
Headquarters
Sweden
Announced
Jan 7, 2026

Products built around digestion

Sigrid sells the Glucose Stabiliser dietary supplement directly to consumers and through a network of US physicians. Its SiPore technology acts locally in the gastrointestinal tract, interacting with enzymes involved in the digestion of carbohydrates and fats.

Commercial growth and a separate medical-device programme

The company is expanding its US business while developing new uses in oral health, veterinary medicine and food technology. It has also submitted a technical dossier for CE marking of an over-the-counter device intended to support weight loss and metabolic health as part of a lifestyle programme.

Sources

  1. Sigrid Therapeutics: funding announcement
  2. BioStock: Sigrid financing
03 / Related rounds

Related funding rounds

01
Series C+ · Biotech

Rakuten Medical

Cancer treatments combining targeted drugs with laser illumination.

Led by TaiAx Life Science Fund
$100M
02
Undisclosed · Energy

Type One Energy

Type One Energy develops stellarator fusion technology and equipment for deployment by utilities and other energy producers.

$87M
03
Undisclosed · Insurance Technology

Gyde

Gyde acquires and supports insurance agencies with AI software and operating resources for client servicing, renewals and business growth.

Led by Lightspeed Venture Partners
$60M